<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font18 { font-size : 18; } .font21 { font-size : 21; } .font23 { font-size : 23; } .font26 { font-size : 26; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font31 { font-size : 31; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font31">treatment </span>
   <span class="font26">patients </span>
   <span class="font23">boceprevir </span>
   <span class="font21">telaprevir </span>
   <span class="font18">;():–. </span>
   <span class="font18">hepatitis </span>
   <span class="font16">Hepatitis </span>
   <span class="font16">cost </span>
   <span class="font16">{border-style </span>
   <span class="font16">HCV </span>
   <span class="font16">SVR </span>
   <span class="font16">px;} </span>
   <span class="font15">#ffffff;} </span>
   <span class="font15">adverse </span>
   <span class="font15">data </span>
   <span class="font15">virus </span>
   <span class="font15">rates </span>
   <span class="font15">randomized </span>
   <span class="font15">weeks </span>
   <span class="font14">$,. </span>
   <span class="font14">Health </span>
   <span class="font14">Medicine </span>
   <span class="font14">chronic </span>
   <span class="font14">events </span>
   <span class="font14">study </span>
   <span class="font14">tolerability </span>
   <span class="font14">Peg-IFN/RBV </span>
   <span class="font14">United </span>
   <span class="font14">cirrhosis </span>
   <span class="font14">clinical </span>
   <span class="font13">(%) </span>
   <span class="font13">Treatment </span>
   <span class="font13">associated </span>
   <span class="font13">based </span>
   <span class="font13">comparative </span>
   <span class="font13">effectiveness </span>
   <span class="font13">vs. </span>
   <span class="font13">Clinical </span>
   <span class="font13">pathogens </span>
   <span class="font13">severe </span>
   <span class="font13">Research </span>
   <span class="font13">Sciences </span>
   <span class="font13">Therapy </span>
   <span class="font13">care </span>
   <span class="font13">medicine. </span>
   <span class="font13">ribavirin </span>
   <span class="font13">sciences </span>
   <span class="font13">telaprevir. </span>
   <span class="font12">States </span>
   <span class="font12">Viral </span>
   <span class="font12">combination </span>
   <span class="font12">compared </span>
   <span class="font12">controlled </span>
   <span class="font12">costs </span>
   <span class="font12">cure </span>
   <span class="font12">infection </span>
   <span class="font12">patient </span>
   <span class="font12">px; </span>
   <span class="font12">use </span>
   <span class="font12">{font-family </span>
   <span class="font12">./NEJMoa </span>
   <span class="font12">Drug </span>
   <span class="font12">Medical </span>
   <span class="font12">Patients </span>
   <span class="font12">Protease </span>
   <span class="font12">Telaprevir </span>
   <span class="font12">acquisition </span>
   <span class="font12">antiviral </span>
   <span class="font12">discontinuation </span>
   <span class="font12">drug </span>
   <span class="font12">drugs </span>
   <span class="font12">font-size </span>
   <span class="font12">leading </span>
   <span class="font12">received </span>
   <span class="font12">trial </span>
   <span class="font12">(%)] </span>
   <span class="font12">Adverse </span>
   <span class="font12">Biology </span>
   <span class="font12">Boceprevir </span>
   <span class="font12">CONSORT </span>
   <span class="font12">Med. </span>
   <span class="font12">Randomized </span>
   <span class="font12">Veterans </span>
   <span class="font12">YFY </span>
   <span class="font12">criteria </span>
   <span class="font12">differences </span>
   <span class="font12">double; </span>
   <span class="font12">experienced </span>
   <span class="font12">formulary </span>
   <span class="font12">generation </span>
   <span class="font12">group </span>
   <span class="font12">life </span>
   <span class="font12">newer </span>
   <span class="font12">outpatient </span>
   <span class="font12">response </span>
   <span class="font12">therapy </span>
   <span class="font12">using </span>
   <span class="font12">veterans </span>
   <span class="font12">viral </span>
   <span class="font11">Administration </span>
   <span class="font11">Affairs </span>
   <span class="font11">Antiviral </span>
   <span class="font11">Cleveland </span>
   <span class="font11">Controlled </span>
   <span class="font11">Engl </span>
   <span class="font11">Food </span>
   <span class="font11">RCTs </span>
   <span class="font11">additional </span>
   <span class="font11">approved </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">early </span>
   <span class="font11">genotype </span>
   <span class="font11">health </span>
   <span class="font11">high </span>
   <span class="font11">higher </span>
   <span class="font11">important </span>
   <span class="font11">infection. </span>
   <span class="font11">information </span>
   <span class="font11">internal </span>
   <span class="font11">pragmatic </span>
   <span class="font11">risk </span>
   <span class="font11">significantly </span>
   <span class="font11">solid; </span>
   <span class="font11">standard </span>
   <span class="font11">trials </span>
   <span class="font11">untreated </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font11">./journal.pone..tTable </span>
   <span class="font11">AEs </span>
   <span class="font11">Annals </span>
   <span class="font11">Cleveland, </span>
   <span class="font11">Cost </span>
   <span class="font11">DAA </span>
   <span class="font11">DAAs </span>
   <span class="font11">DDA </span>
   <span class="font11">Data </span>
   <span class="font11">England </span>
   <span class="font11">Flaviviruses </span>
   <span class="font11">Hepacivirus: </span>
   <span class="font11">Inhibitor </span>
   <span class="font11">Liver </span>
   <span class="font11">Louis </span>
   <span class="font11">Methods </span>
   <span class="font11">Microbial </span>
   <span class="font11">New </span>
   <span class="font11">Ohio, </span>
   <span class="font11">Pragmatic </span>
   <span class="font11">RCT </span>
   <span class="font11">Stokes </span>
   <span class="font11">Study </span>
   <span class="font11">Total </span>
   <span class="font11">Virus </span>
   <span class="font11">access </span>
   <span class="font11">achieved </span>
   <span class="font11">adjudication </span>
   <span class="font11">and/or </span>
   <span class="font11">approval </span>
   <span class="font11">available </span>
   <span class="font11">bold </span>
   <span class="font11">cirrhosis. </span>
   <span class="font11">courier; </span>
   <span class="font11">dasabuvir </span>
   <span class="font11">duration </span>
   <span class="font11">effect </span>
   <span class="font11">efficacy </span>
   <span class="font11">em; </span>
   <span class="font11">group, </span>
   <span class="font11">interferon </span>
   <span class="font11">liver </span>
   <span class="font11">naïve </span>
   <span class="font11">plus </span>
   <span class="font11">primary </span>
   <span class="font11">provide </span>
   <span class="font11">pt;} </span>
   <span class="font11">rate </span>
   <span class="font11">related </span>
   <span class="font11">required </span>
   <span class="font11">routine </span>
   <span class="font11">sample </span>
   <span class="font11">selection </span>
   <span class="font11">sofosbuvir </span>
   <span class="font11">treated </span>
   <span class="font11">treatment. </span>
   <span class="font11">trial. </span>
   <span class="font11">triple </span>
   <span class="font11">used </span>
   <span class="font11">virologic </span>
   <span class="font11">visits </span>
   <span class="font11">weeks. </span>
  </p>
 </body>
</html>
